Birchview Capital’s Apogee Therapeutics APGE Stock Holding History

Birchview Capital’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,000	Closed	-$758K	–	73
2026 Q1	$758K	Sell	9,000 -7,000	-44%	-$508K	0.43%	48
2025 Q4	$1.21M	Hold	16,000	–	–	0.71%	35
2025 Q3	$636K	Hold	16,000	–	–	0.48%	47
2025 Q2	$695K	Buy	16,000 +8,000	+100%	+$304K	0.69%	32
2025 Q1	$299K	Buy	+8,000	New	+$309K	0.26%	46

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Birchview Capital's APGE Position: Q2 2026 in Review

Birchview Capital sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 9,000 shares — an estimated $758K sold.

Birchview Capital first reported a position in APGE in Q1 2025 and held it in 5 quarters. The position peaked at $1.21M in Q4 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Birchview Capital reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
Birchview Capital sold 9,000 Apogee Therapeutics shares in Q2 2026, an estimated $758K.
Birchview Capital first reported a position in Apogee Therapeutics in Q1 2025 and held it in 5 quarters.
Birchview Capital's Apogee Therapeutics position peaked at $1.21M in Q4 2025.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.